Skip to content
AnalystLens

Medpace Holdings Annual Report, Year Ended Dec 31, 2025

Filing Date
Filed February 10, 2026
Period End
December 31, 2025
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’16Oct ’16
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Material agreement8-K · Mar ’21Mar ’21
  4. Material agreement8-K · Apr ’25Apr ’25

Summary

Summary of the 10-K filed February 10, 2026. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported record 2025 results, with net revenue of $2,530,234 thousanda ($2.53 billion), up from $2,109,054 thousand in 2024, and net income of $451,123 thousand ($451.1 million), up from $404,386 thousand.

Income from operations rose to $534,935 thousandb from $446,870 thousand. Diluted EPS was $15.28, compared with $12.63 in 2024. Growth was led by Metabolic, Oncology and Central Nervous System activity, and reimbursed out-of-pocket expenses, which fluctuate with program timing, rose $266.8 million and drove much of the increase in total direct costs.

Net new business awards were $2,646.8 millionc in 2025 versus $2,230.0 million in 2024, and backlog increased $125.0 million, or 4.3%, to $3,027.2 million at December 31, 2025. Approximately $1,890.0 million to $1,910.0 million of that backlog is expected to convert to net revenue in 2026. The filing notes that backlog is contractually terminable without cause and is not necessarily a meaningful predictor of future results.

Capital allocation was dominated by share repurchases. The company repurchased shares for $912.9 milliond in 2025, ended the year with $497.0 million in cash and cash equivalents, and reported no indebtedness. Remaining repurchase authorization was $821.7 million.

The filing also discloses concentration and governance considerations: the top ten customers provided approximately 35.1% of net revenue, and CEO and founder August J. Troendle controls approximately 19.0% of outstanding shares.

Key Highlights

  1. Net revenue of $2.53 billion for 2025, up from $2.11 billion in 2024; net income of $451.1 million, up from $404.4 million
  2. Diluted EPS of $15.28 for 2025 versus $12.63 for 2024
  3. Net new business awards of $2,646.8 million in 2025 versus $2,230.0 million in 2024
  4. Backlog of $3,027.2 million at December 31, 2025, with approximately $1,890.0 million to $1,910.0 million expected to convert to net revenue in 2026
  5. Share repurchases of $912.9 million in 2025 with $821.7 million of remaining authorization; cash and cash equivalents of $497.0 million and no indebtedness at year-end
  6. Customer concentration: top ten customers represented approximately 35.1% of net revenue; 82% of 2025 net revenue came from small biopharmaceutical companies
  7. Governance: CEO and founder August J. Troendle controls approximately 19.0% of outstanding common stock

Financial Statements

FY2025 against FY2024

Line itemFY2025FY2024Change
Revenue$2.53B$2.11B+20.0%
SG&A Expenses$197.56M$180.18M+9.6%
Operating Expenses$2.00B$1.66B+20.0%
Operating Income$534.93M$446.87M+19.7%
Net Income$451.12M$404.39M+11.6%
EPS (Basic)$15.64$13.06+19.8%
EPS (Diluted)$15.28$12.63+21.0%
Shares Outstanding (Basic)28.85M30.96M−6.8%
Shares Outstanding (Diluted)29.53M32.01M−7.8%

Frequently Asked Questions

  1. How did Medpace's revenue and profitability change in 2025?

    Net revenue rose $421.2 million, or 20.0%, to $2,530.2 million. Income from operations increased to $534.9 million from $446.9 million, and net income increased to $451.1 million from $404.4 million. Reimbursed out-of-pocket expenses, which can fluctuate significantly by period, rose $266.8 million and were a major driver of higher total direct costs.

  2. What does the backlog tell investors about future revenue?

    Backlog grew 4.3% to $3,027.2 million at December 31, 2025. The company expects approximately $1,890.0 million to $1,910.0 million to convert to net revenue in 2026. The filing cautions that most contracts can be terminated without cause on 30 days' notice, so backlog may not convert at historical rates and is not necessarily a meaningful predictor of future results.

  3. How is Medpace returning capital to shareholders?

    In 2025 the company repurchased 2,961,924 shares for $912.9 million under its share repurchase program and has not paid dividends. It had $821.7 million of remaining repurchase authorization at year-end. Financing cash outflows were $860.4 million, offset partly by $57.0 million of proceeds from stock option exercises.

  4. What concentration and ownership risks does the filing highlight?

    The top ten customers accounted for approximately 35.1% of 2025 net revenue, and no single customer reached 10%. CEO and founder August J. Troendle controls approximately 19.0% of outstanding shares through direct and beneficial ownership, giving him significant influence over director elections and major corporate transactions.